Latest News and Press Releases

JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential...

JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...

COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2  Data further strengthens value proposition of BiondVax’s...

Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated...

JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...